Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Operating Margin: 2021-2025

Historic Operating Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 13.28%.

  • Kiniksa Pharmaceuticals International's Operating Margin rose 2189.00% to 13.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.38%, marking a year-over-year increase of 1321.00%. This contributed to the annual value of -10.78% for FY2024, which is 145.00% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Operating Margin stood at 13.28% for Q3 2025, which was up 3.30% from 12.86% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Operating Margin peaked at 46.82% during Q3 2022, and registered a low of -253.55% during Q3 2021.
  • Its 3-year average for Operating Margin is -4.83%, with a median of -4.41% in 2023.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Operating Margin skyrocketed by 30,037bps in 2022, and later plummeted by 6,312bps in 2023.
  • Kiniksa Pharmaceuticals International's Operating Margin (Quarterly) stood at -192.75% in 2021, then spiked by 18,867bps to -4.08% in 2022, then skyrocketed by 417bps to 0.10% in 2023, then plummeted by 1,585bps to -15.75% in 2024, then skyrocketed by 2,189bps to 13.28% in 2025.
  • Its Operating Margin was 13.28% in Q3 2025, compared to 12.86% in Q2 2025 and 9.63% in Q1 2025.